Agenda
Tuesday 3rd June
Welcome and introduction
Esteban Jódar and Mehrdad Ariani
09:00 - 09:15
Year in review
Birce Didar Tüt
09:15 - 09:25
Retention status
Mette Neumann Sørensen
09:25 - 09:55
Scientific updates: REDEFINE 1 and 2, SURMOUNT-5 and EASO framework
Cynthia Karenina Osorto Contreras and Carel Le Roux
09:55 - 10:45
Coffee Break
10:45 - 11:15
Weight loss outcomes in REDEFINE 3 – managing patient expectations
Megha Poddar and Carel Le Roux
11:15 - 11:45
Gastrointestinal adverse events in incretin-based therapies
Sean Wharton and Melanie Davies
11:45 - 12:15
Working lunch
12:15 - 13:15
Addressing weight loss concerns in REDEFINE 3
Birce Didar Tüt and Cynthia Karenina Osorto Contreras
13:15 - 15:00
Publication planning
Lucy Donaldson and Pierre Theurey
15:00 - 15:30
Coffee Break
15:30 - 16:00
Further considerations on dose optimisation & tolerability - panel discussion
Silas Hinsch Gylvin, Megha Poddar, and Athena Philis-Tsimikas
16:00 - 16:45
Day 1 close
Esteban Jódar and Mehrdad Ariani
16:45 - 16:50
GEP Dinner
18:30 - 20:30
Wednesday 4th June
Welcome back and day 1 summary
Esteban Jódar and Mehrdad Ariani
09:00 - 09:15
SOUL results
Silas Hinsch Gylvin
09:15 - 09:45
Retaining placebo arm patients – lessons from SELECT
Birce Didar Tüt and Subodh Verma
09:45 - 10:15
Coffee Break
10:15 - 10:45
Retaining placebo arm patients – the steering committee perspective
Matt Cavender
10:45 - 11:15
Retaining placebo arm patients – the operational perspective
Logan Maclay Riboni, and Sarah Walsh
11:15 - 11:45
Retaining placebo arm patients – panel discussion
Logan Maclay Riboni, Matt Cavender and Sarah Walsh
11:45 - 12:15
Looking ahead
Birce Didar Tüt
12:15 - 12:20
Meeting close
Esteban Jódar and Mehrdad Ariani
12:20 - 12:30
Working lunch
12:30 - 13:30
Starting at 09:00 & 17:00 CET
- Key discussion point
09:00
Welcome and introduction
Esteban Jódar and Mehrdad Ariani
- Key discussion point
Time
BREAK
00:00 - 00:00